Follistatin 344

What is Follistatin-344?

Follistatin-344 is one isoform of follistatin, a natural protein your body makes that blocks muscle-limiting signals. It is of interest because it inhibits myostatin, the main brake on muscle growth, which in theory could drive large gains in lean mass. The reality check is important: the eye-catching results come from animals and from gene therapy, and there is no proven injectable follistatin protocol in people.

How Follistatin-344 works

Your body limits how much muscle you build partly through myostatin and activin A, two members of the TGF-beta family that tell muscle to stop growing. Follistatin binds and neutralizes both, effectively releasing that brake. When myostatin is blocked, muscle fibers can grow larger and more numerous in models. This is the same biological pathway behind the naturally heavily muscled animals that have myostatin mutations.

What the research shows

In rodents, sheep, and dogs, blocking myostatin through follistatin gene therapy or recombinant protein produced dramatic muscle-mass increases, in some studies on the order of 20 to 40%, larger than typical anabolic-steroid effects in comparable models. Human evidence is a different and much thinner story. The serious human work has used gene therapy, with early-phase trials in muscle-wasting diseases reporting tolerability and detectable gene expression, but no completed pivotal efficacy trial. An injectable follistatin peptide has not been validated in humans.

Dosage and how it is used

There is no clinically validated injectable dose. Community protocols exist, but they are extrapolated from animal and gene-therapy work rather than from human dose-finding trials, and follistatin is a large, complex protein that does not necessarily behave predictably as an injectable. Treat any protocol as unproven.

→ How to reconstitute Follistatin-344: calculator, units to draw & storage

Side effects and safety

Human safety data for injected follistatin-344 is extremely limited. Powerfully removing the body's brake on tissue growth raises theoretical concerns, and because follistatin and activin have roles beyond muscle, systemic effects are not fully understood. Unregulated sourcing adds purity risk. This is an area where the animal results have run far ahead of validated human use.

• Research depth: dramatic in animals; human work is early-phase gene therapy, not injectable peptide.
• No validated injectable protocol and very limited human safety data.
• Not FDA-approved. Verify current legal and regulatory status independently.

Frequently asked questions

References

• Long-term enhancement of skeletal muscle mass and strength by single gene administration of myostatin inhibitors. PNAS, 2008.
• Follistatin gene therapy in muscle disease: early-phase human trials. PubMed.